2024-03-11 23:59:09 ET
Summary
- Amgen is a solid dividend growth company with a 12-year streak of raising dividends and a healthy payout ratio.
- The company is well-positioned to benefit from increased medical spending and the expansion of its drug portfolio.
- AMGN stock has a potential upside of 14% and the dividend has a growth CAGR in the double digits for the last 10-year period.
Overview
Recently, I've been analyzing different dividend ETFs to determine how they consider a company qualified for a spot in their holdings. Typically, the things that these funds filter for are dividend growth consistency, the CAGR (compound annual growth rate) of the dividend, free cash flow & EPS growth, and a historically positive total return. Reviewing the popular Schwab U.S. Dividend Equity ETF ( SCHD ), I noticed that Amgen ( AMGN ) made the top ten holdings list. As a result, I was curious about how AMGN performed in all of these categories....
Read the full article on Seeking Alpha
For further details see:
Amgen Will Benefit From Increased Medical Spending